| URN | urn:agi-llid:356 |
|---|---|
| Total Entities | 0 |
| Connectivity | 1982 |
| Name | Faslg |
| Description | Fas ligand (TNF superfamily, member 6) |
| Notes | The protein encoded by this gene is the ligand for FAS. Both are transmembrane proteins. Interaction of FAS with this ligand is critical in triggering apoptosis of some types of cells such as lymphocytes. Defects in this gene may be related to some cases of systemic lupus erythematosus (SLE). [provided by RefSeq] |
| Ariadne Ontology | TNF family |
|---|---|
| Secreted proteins | |
| Biofluids assayable substances |
| GO Molecular Function | receptor binding |
|---|---|
| cytokine activity | |
| tumor necrosis factor receptor binding | |
| death receptor binding |
| GO Cellular Component | membrane |
|---|---|
| extracellular region | |
| lysosomal lumen | |
| cytoplasmic membrane-bounded vesicle lumen | |
| membrane raft | |
| external side of plasma membrane | |
| caveola | |
| integral to plasma membrane | |
| integral to membrane | |
| plasma membrane | |
| perinuclear region of cytoplasm | |
| cytoplasmic vesicle | |
| lysosome | |
| cytoplasmic membrane-bounded vesicle | |
| nucleus | |
| extracellular space |
| GO Biological Process | cell-cell signaling |
|---|---|
| positive regulation of I-kappaB kinase-NF-kappaB cascade | |
| positive regulation of epidermal growth factor receptor signaling pathway | |
| signal transduction | |
| apoptotic signaling pathway | |
| extrinsic apoptotic signaling pathway via death domain receptors | |
| negative regulation of transcription from RNA polymerase II promoter | |
| regulation of transcription, DNA-dependent | |
| positive regulation of cell proliferation | |
| induction of necroptosis of activated-T cells | |
| induction of necroptosis by extracellular signals | |
| positive regulation of apoptotic process | |
| induction of apoptosis | |
| positive regulation of neuron apoptotic process | |
| activation of cysteine-type endopeptidase activity involved in apoptotic process | |
| retinal cell programmed cell death | |
| transcription, DNA-dependent | |
| endosomal lumen acidification | |
| cellular chloride ion homeostasis | |
| cellular response to stress | |
| necrotic cell death | |
| apoptotic process | |
| inflammatory cell apoptotic process | |
| immune response | |
| response to growth factor stimulus | |
| response to lipopolysaccharide | |
| negative regulation of angiogenesis |
| Pathway | Apoptosis |
|---|---|
| TNFRSF6 -> HSF1 signaling | |
| TNFRSF5/6 -> RB1/E2F signaling | |
| TNFR -> CREB/ELK-SRF signaling | |
| TNFR -> NF-kB signaling | |
| TNFRSF6 -> DDIT3 signaling | |
| TNFR -> AP-1/ATF/TP53 signaling | |
| TNFRSF6 -> FOXO3A signaling | |
| Doxorubicin-Induced Cardiotoxicity | |
| ROS in Triggering Vascular Inflammation | |
| TGFB1-TGFBR2 Expression Targets | |
| FASLG Expression Targets | |
| NGF/FOXO/MYCN/ELK-SRF Expression Targets | |
| TNF/STAT Expression Targets | |
| TNF/TP53/ATF Expression Targets | |
| ICAM1 Expression Targets | |
| CD247 Expression Targets | |
| FCGR3A Expression Targets | |
| IL15 Expression Targets | |
| IL10 Expression Targets | |
| IL7 Expression Targets | |
| IL2 Expression Targets | |
| IL4 Expression Targets | |
| PRL-GHR/NF-kB/ELK-SRF/MYC Expression Targets | |
| PRL-GHR/STAT Expression Targets | |
| PRL-PRLR Expression Targets | |
| CSF3 Expression Targets | |
| IFNG-IFNR Expression Targets | |
| IFNA1-IFNR Expression Targets | |
| Leptin/ELK-SRF Expression Targets | |
| Leptin/STAT Expression Targets | |
| CCL2 Expression Targets | |
| CCL5 Expression Targets | |
| CCL11 Expression Targets | |
| Dopamine/Gi Expression Targets | |
| GNRH2 Expression Targets | |
| VEGFA/CTNNB/CTNND Expression Targets | |
| VEGFA/NFATC Expression Targets | |
| VEGFA/ATF/CREB/ELK-SRF Expression Targets | |
| Erythropoietin/FOXO3A Expression Targets | |
| HGF/FOXO3A Expression Targets | |
| PDGF/FOXO3A Expression Targets | |
| Epinephrine/Gq Expression Targets | |
| GNRH1 Expression Targets | |
| Morphine Expression Targets | |
| PAF/Gq -> NF-kB Expression Targets | |
| Epinephrine/Gs Expression Targets | |
| VIP Expression Targets | |
| Dopamine/Gs Expression Targets | |
| Noreadrenaline/Gq Expression Targets | |
| POMC Expression Targets | |
| CD8/STAT Expression Targets | |
| CD8/NF-kB Expression Targets | |
| CD8/NFATC Expression Targets | |
| CD8/AP-1 Expression Targets | |
| CD8/ATF/CREB/CREBBP Expression Targets | |
| CD80/STAT Expression Targets | |
| CD80/NF-kB Expression Targets | |
| CD80/NFATC Expression Targets | |
| CD80/AP-1 Expression Targets | |
| CD80/ATF/CREB/CREBBP Expression Targets | |
| CD86/STAT Expression Targets | |
| CD86/NF-kB Expression Targets | |
| CD86/NFATC Expression Targets | |
| CD86/AP-1 Expression Targets | |
| CD86/ATF/CREB/CREBBP Expression Targets | |
| PDCD1/NF-kB Expression Targets | |
| PDCD1/NFATC Expression Targets | |
| PDCD1/AP-1 Expression Targets | |
| PDCD1/ATF/CREB/CREBBP Expression Targets | |
| TCR/STAT Expression Targets | |
| TCR/AP-1 Expression Targets | |
| TCR/CREB/CREBBP/ATF Expression Targets | |
| Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| Insulin/STAT Expression Targets | |
| TCR/NF-kB Expression Targets | |
| VEGFA/STAT Expression Targets | |
| IL1B/PGE2 Expression Targets | |
| TNF/NF-kB Expression Targets | |
| PAF Expression Targets | |
| AGT/CREB Expression Targets | |
| AGT/STAT Expression Targets | |
| EGF/AP-1/ATF Expression Targets | |
| EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| EGF/MEF/MYOD/NFATC Expression Targets | |
| EGF/STAT Expression Targets | |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | |
| Insulin/MEF/MYOD Expression Targets | |
| PAF/Gq -> AP-1/ATF1/CREB/ERK-SRF Expression Targets | |
| TCR/NFAT Expression Targets | |
| TGFB1-ACVRL1 Expression Targets | |
| TGFB1-TGFBR1/AP-1 Expression Targets | |
| TLR4/AP-1 Expression Targets | |
| TNF/AP-1 Expression Targets | |
| VEGFA/AP-1/CREBBP/MYC Expression Targets | |
| EGF/CTNN Expression Targets | |
| drug-gene, gene-chemical, gene-gene interaction pathway | |
| losartan_expanded2 | |
| losartan_expanded3 | |
| losartan-gene, gene-chemical, gene-gene interaction pathway | |
| FasL mediated signaling pathway | |
| FasL mediated signaling pathway | |
| losartan-gene, gene-chemical, gene-gene interaction pathway | |
| losartan-gene, gene-chemical, gene-gene interaction pathway |
| Group | TNF family |
|---|---|
| cell-cell signaling | |
| positive regulation of I-kappaB kinase-NF-kappaB cascade | |
| positive regulation of epidermal growth factor receptor signaling pathway | |
| signal transduction | |
| apoptotic signaling pathway | |
| extrinsic apoptotic signaling pathway via death domain receptors | |
| negative regulation of transcription from RNA polymerase II promoter | |
| regulation of transcription, DNA-dependent | |
| positive regulation of cell proliferation | |
| induction of necroptosis of activated-T cells | |
| induction of necroptosis by extracellular signals | |
| positive regulation of apoptotic process | |
| induction of apoptosis | |
| positive regulation of neuron apoptotic process | |
| activation of cysteine-type endopeptidase activity involved in apoptotic process | |
| retinal cell programmed cell death | |
| transcription, DNA-dependent | |
| endosomal lumen acidification | |
| cellular chloride ion homeostasis | |
| cellular response to stress | |
| necrotic cell death | |
| apoptotic process | |
| inflammatory cell apoptotic process | |
| immune response | |
| response to growth factor stimulus | |
| response to lipopolysaccharide | |
| negative regulation of angiogenesis | |
| receptor binding | |
| cytokine activity | |
| tumor necrosis factor receptor binding | |
| death receptor binding | |
| membrane | |
| extracellular region | |
| lysosomal lumen | |
| cytoplasmic membrane-bounded vesicle lumen | |
| membrane raft | |
| external side of plasma membrane | |
| caveola | |
| integral to plasma membrane | |
| integral to membrane | |
| plasma membrane | |
| perinuclear region of cytoplasm | |
| cytoplasmic vesicle | |
| lysosome | |
| cytoplasmic membrane-bounded vesicle | |
| nucleus | |
| extracellular space | |
| Secreted proteins | |
| Biofluids assayable substances |
| MedScan ID | 356 |
|---|
| Hugo ID | 11936 |
|---|
| Human chromosome position | 1q23 |
|---|
| LocusLink ID | 356 |
|---|---|
| 14103 | |
| 25385 |
| Alias | FASL |
|---|---|
| CD178 | |
| CD95L | |
| ALPS1B | |
| CD95-L | |
| TNFSF6 | |
| APT1LG1 | |
| tumor necrosis factor ligand superfamily member 6 | |
| APTL | |
| CD95 ligand | |
| fas antigen ligand | |
| apoptosis antigen ligand | |
| apoptosis (APO-1) antigen ligand 1 | |
| tumor necrosis factor (ligand) superfamily, member 6 | |
| gld | |
| Fas-L | |
| Faslg | |
| generalized lymphoproliferative disease | |
| CD95L protein | |
| Apoptosis (APO-1) antigen ligand 1 (Fas antigen ligand) | |
| Tumor necrosis factor (ligand) superfamily member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand) | |
| Tumor necrosis factor (ligand) superfamily, member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand) | |
| APO-1 antigen ligand 1 | |
| CD178 antigen | |
| APT1LG I | |
| apoptosis (APO-1) antigen ligand I | |
| Apo1 ligand | |
| OTTHUMP00000032708 | |
| Fas-Ligand | |
| TNF superfamily, member 6 | |
| TNF6 | |
| TNF6_HUMAN | |
| tumor necrosis factor (ligand) superfamily, member VI | |
| tumour necrosis factor (ligand) superfamily, member 6 | |
| tumour necrosis factor (ligand) superfamily, member VI | |
| fas ligand | |
| Fas ligand (TNF superfamily, member 6) | |
| FAS L | |
| tumor necrosis factor (ligand) superfamily member 6 (apoptosis | |
| Tnfsf6s |
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| OMIM ID | 134638 |
|---|---|
| 211980 | |
| 152700 |
| Unigene ID | Hs.2007 |
|---|---|
| Mm.3355 | |
| Rn.9725 |
| KEGG ID | hsa:356 |
|---|---|
| mmu:14103 | |
| rno:25385 |
| Swiss-Prot Accession | P48023 |
|---|---|
| Q53ZZ1 | |
| Q99PH8 | |
| P41047 | |
| Q544E9 | |
| P36940 | |
| Q61217 | |
| Q9R1F2 | |
| Q9BZP9 | |
| Q0VHD7 | |
| Q7TMV9 |
| GO ID | 0005125 |
|---|---|
| 0005102 | |
| 0005164 | |
| 0006919 | |
| 0008633 | |
| 0006915 | |
| 0007267 | |
| 0030644 | |
| 0033554 | |
| 0048388 | |
| 0008625 | |
| 0006955 | |
| 0006917 | |
| 0060555 | |
| 0060554 | |
| 0006925 | |
| 0070265 | |
| 0016525 | |
| 0000122 | |
| 0043123 | |
| 0043065 | |
| 0008284 | |
| 0045742 | |
| 0043525 | |
| 0070848 | |
| 0032496 | |
| 0046666 | |
| 0007165 | |
| 0006351 | |
| 0005901 | |
| 0060205 | |
| 0009897 | |
| 0005576 | |
| 0005615 | |
| 0005887 | |
| 0043202 | |
| 0005634 | |
| 0048471 | |
| 0097190 | |
| 0006355 | |
| 0016023 | |
| 0031410 | |
| 0016021 | |
| 0005764 | |
| 0016020 | |
| 0045121 | |
| 0005886 | |
| 0005123 | |
| 0008624 |
| PIR ID | A53062 |
|---|---|
| I38707 | |
| A49266 |
| Swiss-Prot ID | TNFL6_MOUSE |
|---|---|
| TNFL6_HUMAN | |
| TNFL6_RAT | |
| Q53ZZ1_HUMAN | |
| Q544E9_MOUSE |
| Cell Localization | Cell membrane |
|---|---|
| Cytoplasmic vesicle lumen | |
| Lysosome lumen | |
| Secreted | |
| Nucleus | |
| Extracellular |
| IPI ID | IPI00110272 |
|---|---|
| IPI00227798 | |
| IPI00007577 | |
| IPI00220870 | |
| IPI00326685 | |
| IPI00462905 | |
| IPI00781706 |
| Mouse chromosome position | 1 85.0 cM |
|---|
| Rat chromosome position | 13q22 |
|---|
| Homologene ID | 533 |
|---|
| MGI ID | 99255 |
|---|
| RGD ID | 3880 |
|---|
| Primary Cell Localization | Extracellular |
|---|